In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...

12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq ... that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor ...

To meet the requirements of the Education and Care Services National Regulations 2011, early childhood professionals who work with children need to be aware of the existence and application of current ...

Businesses are at a critical juncture, as their workplaces evolve, they must reassess how they secure their most valuable assets – their data, networks, and people. The rapid shift to remote and ...